Trilc.Is

TRILC.IS has a debt-to-equity ratio of 1.57, indicating a relatively high level of leverage, and a current ratio of 1.04, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -817.91 million TRY, while operating cash flow is positive at 613.90 million TRY, highlighting a mismatch between operating performance and capital expenditure. The negative cash and equivalents position of -65,640 TRY further signals liquidity constraints.

The company's profitability metrics are weak, with a return on equity of -38.38% and a return on assets of -9.04%, both significantly below the industry median for pharmaceutical firms. These figures suggest operational inefficiencies or declining margins, which could be a concern for investors.

TRILC.IS's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional economic or regulatory risks. The company's capital expenditure of -256.11 million TRY indicates a net outflow, potentially signaling investment in long-term growth or asset write-downs.

Looking ahead, the company's revenue is expected to remain flat or decline in the next fiscal year, with no significant growth drivers identified in the latest filings. The net income of -622.65 million TRY suggests ongoing profitability challenges, and the outlook for margins is negative due to high debt servicing costs and weak operating performance.

The risk assessment highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential refinancing or liquidity pressures in the near term. No dilution sources are identified in the latest filings, and the dilution near-term probability is low.

Recent filings and transcripts do not disclose any material events or strategic shifts that would significantly alter the company's trajectory. The absence of recent capital raises or major product launches suggests a period of operational stability or stagnation.